Koers Acasti Pharma Inc Toronto S.E.
Aandelen
APO
CA00430K4028
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 37,31 mln. 27,28 mln. 25,53 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -18 mln. -13,16 mln. -12,31 mln. | Nettowinst (verlies) 2025 * | -23 mln. -16,81 mln. -15,74 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,05
x | K/w-verhouding 2025 * |
-2,64
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 83,98% |
Recentste transcriptie over Acasti Pharma Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Prashant Kohli
CEO | Chief Executive Officer | 52 | 01-08-21 |
Director of Finance/CFO | 52 | 05/01 | |
Carrie D'Andrea
CTO | Chief Tech/Sci/R&D Officer | 52 | 08-05-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
A. Davis
BRD | Director/Board Member | 57 | 10-10-23 |
Director/Board Member | - | 10-10-23 | |
Santosh Kottayil
BRD | Director/Board Member | - | 10-10-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |